Medicare's prospective payment system for long-term acute-care hospitals (LTCHs) provides modest reimbursements at the beginning of a patient's stay before jumping discontinuously to a large lump-sum payment after a prespecified number of days. We show that LTCHs respond to the financial incentives of this system by disproportionately discharging patients after they cross the large-payment threshold. We find this occurs more often at for-profit facilities, facilities acquired by leading LTCH chains, and facilities colocated with other hospitals. Using a dynamic structural model, we evaluate counterfactual payment policies that would provide substantial savings for Medicare.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience.
Hematol Oncol
January 2025
Department of Laboratory and Haematological Sciences, Haematology Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.
Cluster analysis of sarcopenia in older adults: significant factors contributing to disease severity.
Eur Geriatr Med
January 2025
Federal State Autonomous Educational Institution of Higher Education "Russian National Research Medical University named after N.I. Pirogov" of the Ministry of Health of the Russian Federation, Separate structural unit "Russian Gerontology Research and Clinical Centre", 16 1st Leonova Street, Moscow, Russia, 129226.
Introduction: The European Working Group on Sarcopenia in Older People (EWGSOP2) defines sarcopenia as a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age. New findings on the hormonal and metabolic characteristics of patients with sarcopenia have aided in developing more targeted therapeutic strategies. However, treating older patients with sarcopenia still poses a number of challenges.
View Article and Find Full Text PDF[Global surgery-Challenges in the treatment of children with cleft lip and palate].
Chirurgie (Heidelb)
January 2025
Klinik für Mund‑, Kiefer- und Plastische Gesichtschirurgie, Zentrum für Zentrum für Lippen-Kiefer-Gaumenspalten und seltene oro-kranio-faziale Fehlbildungen, Universitätsmedizin Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Deutschland.
Background: Cleft lip and palate is the most frequent malformation in humans that requires surgical correction but is not primarily life-threatening. That is why in many economically not very well developed countries, special surgical care, such as for cleft lip and palate, is not guaranteed at all or is not sufficiently guaranteed, so that numerous aid organizations have been founded for over 50 years to provide help by organizing surgical aid missions. Even if this help seems primarily ethically harmless and very laudable, the lack of rules and instructions unfortunately regularly leads to the fact that legal, ethical and even medical treatment standards are often not observed to the detriment of the affected children.
View Article and Find Full Text PDF"MINIMIZING THIGHPLASTY COMPLICATIONS: A COMBINED APPROACH OF J MEDIAL PATTERN AND HELIUM-PLASMA ASSISTED LIPOSCULPTURE".
Plast Reconstr Surg
January 2025
Department of Plastic Surgery, Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy.
Thighplasty is a widely performed body contouring procedure, utilizing various surgical techniques for thigh lifting, including medial scar positioning, vertical and horizontal procedures, and liposuction. Despite its popularity, thighplasty is associated with high complication rates and suboptimal postoperative outcomes.This article presents a novel technique: the J medial thighplasty combined with helium plasma radiofrequency technology (HPRF) to address moderate skin and soft-tissue laxity and ptosis in the inner thighs.
View Article and Find Full Text PDFIdentification of USP2 as a novel target to induce degradation of KRAS in myeloma cells.
Acta Pharm Sin B
December 2024
Hongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Inducing the degradation of KRAS represents a novel strategy to combat cancers with KRAS mutation. In this study, we identify ubiquitin-specific protease 2 (USP2) as a novel deubiquitinating enzyme of KRAS in multiple myeloma (MM). Specifically, we demonstrate that gambogic acid (GA) forms a covalent bond with the cysteine 284 residue of USP2 through an allosteric pocket, inhibiting its deubiquitinating activity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!